RxDoctor Payments DataLook up a doctor →

Ann Jefferds, MD

Pulmonary Disease · Salt Lake City, UTNPI 1386691558

Payments from drug & device makers

$8,692in general payments, 2019–2025

Across 515 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$798
  • Lilly USA, LLC$729
  • Amgen$685
  • Pfizer$684
  • Viiv Healthcare Company$563
  • Boehringer Ingelheim$506
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$8,692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,692 in reported general payments places this provider in the 70th percentile of 101 pulmonary disease providers in Utah.

See all pulmonary disease providers in Utah

Medicare billing

Part B allowed, 2024
$57,197
Medicare patients
162
Services billed
670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$76,677
OzempicSemaglutide53$56,169
EliquisApixaban40$43,354
MounjaroTirzepatide16$18,873
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$15,037
JardianceEmpagliflozin11$13,782
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$9,190
SymbicortBudesonide/Formoterol Fumarate17$6,194
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$5,258
MovantikNaloxegol Oxalate12$5,021
Albuterol Sulfate HfaAlbuterol Sulfate94$4,043
Atorvastatin Calcium371$4,028
Omeprazole148$3,065
Levothyroxine Sodium197$2,401
Olmesartan Medoxomil130$2,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$350$76,67767 claims
Novo NordiskOzempic$291$56,16953 claims
PfizerEliquis$684$43,35440 claims
Boehringer IngelheimJardiance, Stiolto Respimat$506$22,97222 claims
AstraZenecaBreztri Aerosphere, Symbicort$170$21,23131 claims
Lilly USA, LLCMounjaro$729$18,87316 claims
AbbVieSynthroid$798$1,01517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 101 pulmonary disease providers in Utah.

Other pulmonary disease in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →